Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.
The UAB Division of Pulmonary, Allergy and Critical Care Medicine is an integral part of one of the nation's largest health systems. Nationally known for our compassionate care, cutting-edge research, ...
What is cystic fibrosis liver disease? Liver disease associated with cystic fibrosis (CF) has been increasingly diagnosed during recent years, most likely due to the combined effect of systematic ...
Fibrocystic breasts occur when hormonal changes make breast tissue take on a lumpy or rope-like texture. They can be painful but it's completely harmless. Once called fibrocystic breast disease, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback